CEACAM1 mediated protective immunity
US8735157B2 · kind B2 · utility
1Cited by
1References
3Claims
0Family size
Inventor
Key dates
| Filing date | Jun 9, 2006 |
| Grant date | May 27, 2014 |
| Priority date | — |
| Expiry date | Mar 2, 2027 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70596
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the suppression of immune responses in a targeted fashion, by increasing the functional concentration of the CEACAM1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.